Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Frequently asked questions
What sector does Caribou Biosciences Inc (CRBU) operate in?
Caribou Biosciences Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Caribou Biosciences Inc (CRBU) current stock price?
As of the latest data, Caribou Biosciences Inc stock price is $1.58, with a previous close of $1.61. Caribou Biosciences Inc lost -$0.03 in the last trading session, representing a -1.86% loss.
What is Caribou Biosciences Inc (CRBU) current market capitalization?
Caribou Biosciences Inc market cap is approximately 156.71 million.
What is Caribou Biosciences Inc (CRBU) Earnings Per Share (EPS)?
The trailing EPS is -$1.42, and the forward EPS is -$1.40.
What is Caribou Biosciences Inc (CRBU) EBITDA?
Caribou Biosciences Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -24.44 million.
Does Caribou Biosciences Inc (CRBU) pay dividends?
No. Caribou Biosciences Inc does not pay a dividend.
How did Caribou Biosciences Inc (CRBU) perform in its most recent earnings report?
In the last report (June 30, 2026), Caribou Biosciences Inc posted an EPS surprise of 16.13% and a revenue surprise of 9.88%.
What is Caribou Biosciences Inc (CRBU) beta (volatility) score?
Caribou Biosciences Inc has a beta of 2.276, indicating very high volatility compared to the market.
